Friedberg Ezra M 4/A
4/A · Pelthos Therapeutics Inc. · Filed Apr 1, 2026
Research Summary
AI-generated summary of this filing
Pelthos (PTHS) Director Ezra Friedberg Receives RSU Awards
What Happened
- Ezra M. Friedberg, a director of Pelthos Therapeutics Inc. (PTHS), received restricted stock unit (RSU) awards (compensation grants) on three dates. The grants reported are: 6,450 RSUs (6/14/2024), 2,454 RSUs (11/13/2024), and 19,108 RSUs (7/02/2025), totaling 28,012 RSUs. Each award was reported at $0.00 purchase price (awarded as compensation). This filing is an AMENDED Form 4 that reformats prior reporting (see footnotes).
Key Details
- Transaction dates and amounts:
- 2024-06-14 — 6,450 RSUs @ $0.00
- 2024-11-13 — 2,454 RSUs @ $0.00
- 2025-07-02 — 19,108 RSUs @ $0.00
- Total RSUs granted (sum): 28,012 RSUs (amounts adjusted for a 1-for-10 reverse split per footnote).
- Shares owned after transaction: not specified in this amendment (filing reports the grants; check company filings for current beneficial ownership).
- Notable footnotes:
- F1: This amendment moves previously reported RSU grants into Table I; original Form 4s for these grants were filed between June 18, 2024 and July 7, 2025.
- F2: RSUs were awarded as board compensation and vest in equal quarterly installments over three years, conditioned on continued service.
- F3: Reported amounts reflect a 1-for-10 reverse stock split on July 1, 2025.
- F4: Mr. Friedberg is manager of Balmoral Financial Group LLC and Key Recovery Group LLC; he disclaims beneficial ownership of shares held by those entities except for any pecuniary interest.
- Filing timeliness: This is an amended filing (filed 2026-04-01) that restates earlier Form 4 reporting; consult the original filings for the initial reporting dates and timeliness.
Context
- RSUs are compensation awards that convert into shares according to vesting terms; these awards were not purchases and involved no cash outlay at grant. The awards vest quarterly over three years and may be settled solely in Pelthos common stock when vested.
- Awards to directors are common as part of board compensation and do not by themselves indicate buying or selling intent. For a full picture of insider interest, compare these grants to subsequent vesting, any sales, and overall insider holdings.
Insider Transaction Report
Form 4/AAmended
Friedberg Ezra M
Director
Transactions
- Award
Common Stock
[F1][F2][F3]2024-06-14+6,450→ 61,023 total - Award
Common Stock
[F1][F2][F3]2024-11-13+2,454→ 63,477 total - Award
Common Stock
[F1][F2]2025-07-02+19,108→ 82,585 total
Holdings
- 82,072(indirect: By LLC)
Common Stock
[F3][F4] - 40,000(indirect: By LLC)
Common Stock
[F3][F4]
Footnotes (4)
- [F1]From June 18, 2024 to July 7, 2025, the reporting person filed multiple Form 4s relating to shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4s filed by the reporting person (the "Original Form 4s"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4s in order to report the grant of such RSUs in Table I.
- [F2]The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary.
- [F3]Amounts have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.
- [F4]Ezra Friedberg is the manager of Balmoral Financial Group LLC ("Balmoral") and the manager of Key Recovery Group LLC ("Key"). By virtue of these relationships, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.
Signature
/s/ Francis Knuettel II, by power of attorney|2026-04-01